Optimal diabetes care outcomes following face-to-face medication therapy management services

Population Health Management

Volumn 16, Issue 1, 2013, Pages 28-34

  Brummel, Amanda R ^a   Soliman, Ahmed M ^b   Carlson, Angeline M ^c   De Oliveira, Djenane Ramalho ^a  

^a Fairview Pharmacy Services   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c Data Intelligence Consultants LLC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIDIABETIC AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HEMOGLOBIN A1C; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN;

ADULT; ARTICLE; BLOOD PRESSURE; CHARLSON SCORE; DIABETES MELLITUS; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICATION THERAPY MANAGEMENT; OUTCOME ASSESSMENT; SCORING SYSTEM; TOBACCO;

COMMUNITY PHARMACY SERVICES; DIABETES MELLITUS; DISEASE MANAGEMENT; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MEDICARE PART D; MEDICATION THERAPY MANAGEMENT; MIDDLE AGED; UNITED STATES;

EID: 84873849509     PISSN: 19427891     EISSN: 19427905     Source Type: Journal    
DOI: 10.1089/pop.2012.0023     Document Type: Article

References (24)

1. Ernst FR, Grizzle AJ. Drug-related morbidity and mortality: Updating the cost-of-illness model. J Am Pharm Assoc (Wash) 2001;41:192-199.
2. Hepler CD, Strand LM. Opportunities and responsibilities in pharmaceutical care. Am J Hosp Pharm 1990;47:533-543.
3. Medicare Prescription Drug, Improvement, and Modernization Act of 2003. Available at: http://www.gpo.gov/fdsys/pkg/PLAW-108publ173/html/PLAW-108publ173. htm. Accessed March 1, 2012.
4. Chrischilles EA, Carter BL, Lund BC, et al. Evaluation of the Iowa Medicaid pharmaceutical case management program. J Am Pharm Assoc (2003) 2004;44:337-349.
5. Isetts BJ, Schondelmeyer SW, Artz MB, et al. Clinical and economic outcomes of medication therapy management services: The Minnesota experience. J Am Pharm Assoc (2003) 2008;48:203-211; 3 p following 211.
6. Bunting BA, Cranor CW. The Asheville project: Longterm clinical, humanistic, and economic outcomes of a community-based medication therapy management program for asthma. J Am Pharm Assoc (2003) 2006;46:133-147.
7. Smith SR, Clancy CM. Medication therapy management programs: Forming a new cornerstone for quality and safety in Medicare. Am J Med Qual 2006;21:276-279.
8. Cranor CW, Bunting BA, Christensen DB. The Asheville project: Long-term clinical and economic outcomes of a community pharmacy diabetes care program. J Am Pharm Assoc (Wash) 2003;43:173-184.
9. Murray MD, Ritchey ME, Wu J, Tu W. Effect of a pharmacist on adverse drug events and medication errors in outpatients with cardiovascular disease. Arch Intern Med 2009;169: 757-763.
10. Murray MD, Young J, Hoke S, et al. Pharmacist intervention to improve medication adherence in heart failure: A randomized trial. Ann Intern Med 2007;146:714-725.
11. MN Community Measurement. Measuring and reporting health care quality in Minnesota. Available at: http://www.mncm.org/site/. Accessed February 28, 2012.
12. Ramalho de Oliveira D, Brummel AR, Miller DB. Medication therapymanagement: 10 years of experience in a large integrated health care system. J Manag Care Pharm 2010;16:185-195.
13. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992;45:613-619.
14. Ai C, Norton EC. Interaction terms in logit and probit models. Econ Lett 2003;80:123-129.
15. Karaca-Mandic P, Norton EC, Dowd B. Interaction terms in nonlinear models. Health Serv Res 2012;47:255-274.
16. Bertrand M, Duflo E, Mullainathan S. How much should we trust differences-in-differences estimates? Quart J Econ 2004; 119:249-275.
17. Toscani M, O'Connor JP, Nash DB. A decentralized, patientcentered approach to diabetes disease management in the primary care setting. Dis Manag 2001;4:163-171.
18. Johnson KA, Chen S, Cheng IN, et al. The impact of clinical pharmacy services integrated into medical homes on diabetes-related clinical outcomes. Ann Pharmacother 2010;44: 1877-1886.
19. Branham A, Moose J, Ferreri S. Retrospective analysis of medication adherence and cost following medication therapy management. (Article 12) Innov Pharm 2010;1:1-8.
20. Al-Delaimy WK, Manson JE, Solomon CG, et al. Smoking and risk of coronary heart disease among women with type 2 diabetes mellitus. Arch Intern Med 2002;162:273-279.
21. Haire-Joshu D, Glasgow RE, Tibbs TL. Smoking and diabetes. Diabetes Care 1999;22:1887-1898.
22. Al-Delaimy WK, Willett WC, Manson JE, Speizer FE, Hu FB. Smoking and mortality among women with type 2 diabetes: The nurses' health study cohort. Diabetes Care 2001;24: 2043-2048.
23. Serraino D, Franceschi S, Tassan M, Baron AE, Talamini R. Cigarette smoking recidivism after participation in the "fiveday plan to stop smoking" in northeastern Italy. Prev Med 1993;22:272-283.
24. Rhee MK, Slocum W, Ziemer DC, et al. Patient adherence improves glycemic control. Diabetes Educ 2005;31:240-250.